Table 1.

Published cases of omalizumab use in urticarial vasculitis

References	Details	Age (years)	Complement levels	Systemic symptoms	Omalizumab		Effect of omalizumab
					Frequency (weeks)	Dose (mg)
Del Pozo et al. [7]	Female with systemic lupus erythematosus (SLE)	51	Normal C3, low C4	Arthralgia (SLE)	Unknown, based on weight and IgE level		Partial resolution after 3 × doses
Varricchi et al. [8]	Female with Churg-Strauss syndrome (CSS)	44	Unknown	Asthma (CSS)	2	300	Complete, immediate resolution
Diez et al. [2]	Female	51	Normal	No	4	150	Complete resolution after 4–5 doses, relapse on cessation
	Female	54	Unknown	No	4	150
	Female	28	Normal	No	4	300	Complete immediate resolution, relapse on cessation
Sussman et al. [3]	Unspecified adult		Unknown	Unknown	2	150	Complete resolution
Kai et al. [6]	Unspecified adult		Normal	No	4	150	Response, relapse on cessation
Ghazanfar et al. [4]	Male	68	Unknown	No	4	300	Complete resolution
Aurich et al. [9]	Female	36	Low C3 and C4	Nephrotic syndrome	4	300–600	No response over 19 months
Nucera et al. [10]	Female	47	Low C3 (0.17 g/L), normal C1q and anti C1q	No major organ dysfunction but arthralgia/abdominal pain	4	300	Complete resolution after 2nd injection. Complement levels returned to normal. Relapse on treatment cessation